8月8日，據(jù)國外知名網(wǎng)站“Fierce Pharma”報(bào)道，拜耳和禮藍(lán)（Elanco）的動保業(yè)務(wù)將在下周合并。
8月8日，據(jù)國外知名網(wǎng)站“Fierce Pharma”報(bào)道，拜耳和禮藍(lán)（Elanco）的動保業(yè)務(wù)將在下周合并。
一年前拜耳可能計(jì)劃剝離動保業(yè)務(wù)的傳言剛出現(xiàn)的時(shí)候，從禮來（Eli Lilly）獨(dú)立而出的禮藍(lán)（Elanco）并不是市場觀察者的買家列表中可能性最高一家，尤其是在幾家私募投資公司對其表示明顯興趣之后。
據(jù)路透社援引某業(yè)內(nèi)人士的消息稱，兩家公司可能最快會在下周宣布達(dá)成合并協(xié)議。該知情人士稱，交易的一部分禮藍(lán)將使用股票支付，具體可能會在下周的季度報(bào)告中宣布。
對于FiercePharma網(wǎng)站的評論，禮藍(lán)的一位發(fā)言人拒絕回應(yīng)。而拜耳的一位發(fā)言人在電子郵件中表示，該公司正在退出動保業(yè)務(wù)的“路上”?！霸趯ν顺鰟颖I(yè)務(wù)的方案進(jìn)行戰(zhàn)略評估后，主要關(guān)注點(diǎn)是出售，然而拜耳也繼續(xù)考慮所有價(jià)值最大化的選項(xiàng)。”他說。
以下為Fierce Pharma網(wǎng)站原文：
Bayer, Elanco could lock up animal health merger next week: report
When rumors emerged nearly a year ago that Bayer might be planning to exit the animal-health business, Eli Lilly spinoff Elanco was not at the top of any market-watcher’s list of potential buyers—especially not after it became clear that several private equity players were interested in the asset.
Turns out Elanco was interested, and the two companies could announce an agreement to merge as soon as next week, Reuters reports, citing unnamed sources. Elanco would pay for the deal partly in stock, and it could be aiming to time the announcement with its quarterly report next week, the sources said.
A spokesperson for Elanco declined to comment to FiercePharma. A spokesperson for Bayer said in an email that the company is “on track” to exit animal health. “Following a strategic review of exit options, the primary focus is on a sale. However, Bayer also continues to consider all value-maximizing options,” he said.
來源：Fierce Pharma
翻譯：農(nóng)財(cái)寶典記者王之嫻
